Enhanced productivity and functionality of Modified Ribosomally Produced Peptides (M-RIPPs)

增强修饰核糖体产生的肽 (M-RIPP) 的生产力和功能

• 批准号: 102299
• 金额: $ 61.74万
• 依托单位: INGENZA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102299
• 关键词: Enhanced; productivity; functionality; Modified; Ribosomally

Ribosomally Produced Peptides (RIPPs) are widely recognised as one of the most promising classes of compounds with the potential to treat many diseases including infection, cancer & inflammation. They are of great interest to the pharma industry, but are extremely costly to produce/modify - even in milligram amounts. Through the utilisation of cutting-edge techniques in combinatorial synthetic biology, this project sets out to achieve a world first; namely, to produce bespoke libraries of Modified RIPPs (M-RIPPs) in sufficient quantities to permit drug discovery screening. The project combines the fundamental knowledge of the natural processes involved in RIPP biosynthesis of the two premier UK academic groups active in the field with the applied expertise in industrial biosynthesis of a leading UK IB company. It will deliver a versatile yet robust technology platform for the production of M-RIPPs that will be commercialised via a new UK spinout company.

核糖体产生的肽（RIPPs）被广泛认为是最有前途的一类化合物，具有治疗多种疾病的潜力，包括感染，癌症和炎症。它们对制药行业非常感兴趣，但生产/修改成本极高-即使是毫克量。通过利用组合合成生物学的尖端技术，该项目旨在实现世界第一;即，生产足够数量的修饰RIPPs（M-RIPPs）的定制库，以允许药物发现筛选。该项目结合了两个主要的英国学术团体在该领域的RIPP生物合成所涉及的自然过程的基本知识，以及英国领先的IB公司在工业生物合成方面的应用专业知识。它将为M-RIPPs的生产提供一个多功能而强大的技术平台，该平台将通过一家新的英国分拆公司进行商业化。